ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
- Conditions
- Endometriosis
- Interventions
- Drug: Placebo for E2/NETA
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 681
- Registration Number
- NCT03213457
- Locations
- 🇺🇸
Clinical Research Adv, Inc. /ID# 149257, Puyallup, Washington, United States
🇺🇸Tidewater Clinical Research /ID# 145397, Virginia Beach, Virginia, United States
🇺🇸Atlanta Women's Research Inst /ID# 145543, Atlanta, Georgia, United States
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 230
- Registration Number
- NCT03212521
- Locations
- 🇺🇸
Univ Maryland School Medicine /ID# 161157, Baltimore, Maryland, United States
🇺🇸Digestive Disease Associates - Baltimore /ID# 161260, Baltimore, Maryland, United States
🇺🇸University of Vermont Medical Center /ID# 161263, Burlington, Vermont, United States
A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
- Conditions
- Hepatitis C Virus (HCV)
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 505
- Registration Number
- NCT03201718
- Locations
- 🇰🇷
Kyungpook National Univ Hosp /ID# 168731, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Dong-A University Hospital /ID# 167362, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Yeungnam University Med Ctr /ID# 167425, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
- Conditions
- Lymphoblastic LymphomaAcute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 69
- Registration Number
- NCT03181126
- Locations
- 🇺🇸
City of Hope /ID# 169029, Duarte, California, United States
🇺🇸LPCH Stanford /ID# 163337, Palo Alto, California, United States
🇺🇸University of Chicago /ID# 163369, Chicago, Illinois, United States
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 187
- Registration Number
- NCT03178487
- Locations
- 🇸🇪
Reumatologkliniken /ID# 165713, Vaesteras, Sweden
🇺🇸Bay Area Arthritis and Osteo /ID# 165023, Brandon, Florida, United States
🇺🇸St. Lukes Clinic /ID# 165827, Meridian, Idaho, United States
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
- Conditions
- Uveitis
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 155
- Registration Number
- NCT03155243
- Locations
- 🇦🇹
Medizinische Universität Graz /ID# 206301, Graz, Steiermark, Austria
🇦🇹Medical University of Vienna /ID# 206190, Vienna, Wien, Austria
🇨🇴Clinica Oftalmologica del Caribe /ID# 206448, Barranquilla, Atlantico, Colombia
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
- Conditions
- EndocarditisBacteremia
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2
- Registration Number
- NCT03148756
- Locations
- 🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 19
- Registration Number
- NCT03145909
- Locations
- 🇺🇸
City of Hope /ID# 161079, Duarte, California, United States
🇺🇸Yale University /ID# 201357, New Haven, Connecticut, United States
🇺🇸St. Lukes Cancer Institute /ID# 201353, Kansas City, Missouri, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT03145948
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 164101, Anaheim, California, United States
🇺🇸Providence Clinical Research /ID# 163867, Toluca, California, United States
🇺🇸Abbvie Clinical Pharmacology Research Unit /ID# 163866, Grayslake, Illinois, United States
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT03138408
- Locations
- 🇺🇸
Highlands Oncology Group /ID# 209165, Fayetteville, Arkansas, United States
🇺🇸City of Hope /ID# 202493, Duarte, California, United States
🇺🇸The Ohio State University - Columbus /ID# 164089, Columbus, Ohio, United States